| 2025-11-12 |
复牌提示：
2025-11-12 09:56:09 停牌，复牌日期 2025-11-12 10:01:09
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本132.72万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-6.88美元,归母净利润-910.3万美元,同比去年增长38.07%
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-4.51美元,归母净利润-597万美元,同比去年增长44.80%
|
| 2025-07-03 |
详情>>
内部人交易：
Winslow Garrett等共交易6笔
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-1.92美元,归母净利润-253.3万美元,同比去年增长53.75%
|
| 2025-04-30 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect Carl Goldfischer, M.D. and David Shapiro, M.D. as Class II members of the Board of Directors, to serve until the Company’s 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal;
2.To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of common stock upon conversion of the Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024;
3.To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
|
| 2025-03-19 |
详情>>
业绩披露：
2024年年报每股收益-18.53美元,归母净利润-2143.9万美元,同比去年增长44.10%
|
| 2024-11-01 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-13.3美元,归母净利润-1469.8万美元,同比去年增长53.89%
|
| 2024-08-30 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.4美元,归母净利润-1081.5万美元,同比去年增长54.44%
|
| 2024-04-29 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect Anne Prener, M.D., as a Class I member of the Board of Directors, to serve until the Company’s 2027 Annual Meeting of Stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal;
2.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company’s common stock at a ratio of not less than 1-for-4 and not greater than 1-for-25 (or any number in between), with the exact ratio, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors at any time within one year of the date of the Annual Meeting without further approval or authorization from the Company’s stockholders (the “Reverse Stock Split");
3.To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
|
| 2024-04-29 |
详情>>
业绩披露：
2024年一季报每股收益-0.2美元,归母净利润-547.7万美元,同比去年增长57.85%
|
| 2024-03-08 |
详情>>
业绩披露：
2023年年报每股收益-1.44美元,归母净利润-3834.9万美元,同比去年增长37.77%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.21美元,归母净利润-3187.4万美元,同比去年增长32.97%
|
| 2023-07-31 |
详情>>
业绩披露：
2023年中报每股收益-0.91美元,归母净利润-2373.8万美元,同比去年增长29.82%
|
| 2023-04-28 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect Jayson Dallas, M.D., Amit Munshi and Hans Schambye, Ph.D., M.D., as Class III members of the board of directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal;
2.To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
|
| 2022-04-28 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.To elect Carl Goldfischer, M.D. and David Shapiro, M.D., as Class II members of the board of directors, to serve until the Company’s 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal;
2.To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-14 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect Chau Q. Khuong, Sren Mller, Ph.D. and Anne Prener, M.D. as Class I members of the board of directors, to serve until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
|